Life Sciences
for UK Life Sciences in December 2011. The Strategy recognises the centrality of the NHS
to a high-performing UK health and life sciences ecosystem. It is a bold ambition to accelerate the UK’s leadership of 21st century medicine and healthcare technology, and ensure the UK is the best place in the world for foreign companies to invest in the life sciences industry. By lowering development costs through an accelerated path to market, the government can encourage investment in medical science, while also producing affordable treatments for the NHS. This will further improve the nation’s healthcare by speeding up NHS adoption of state-of- the-art medical advances. Such is the impetus on the sector in July 2014
Prime Minister David Cameron appointed the first UK Minister for Life Sciences. This role is underpinned by the new joint Office for Life Sciences which leads the government’s efforts to harness the UK’s science base and unique NHS, to improve healthcare and contribute to economic growth. This fresh approach could significantly reduce the time it takes to develop new medicines, devices and diagnostics, by taking an ‘end to end’ view of medicine, from discovery through to patient use. It is a step change to the previous model, taking all the components of the lengthy drug production line and making them work simultaneously. Ground-breaking developments in genomics and digital technology mean personalised health could play a significant role in the future of healthcare, helping to prevent and treat diseases now and in the future. The commitment to leadership of 21st century
healthcare extends beyond the realms of academic and clinical research, and strives to find innovative ways to use digital tools, data and technology to transform patients’ lives. The adoption of telemedicine and telehealth brings new sectors such as telecommunications and technology providers into the conversation. Comprehensive ongoing monitoring provides more data, which helps physicians develop the best treatment plan. The increased data availability may also give
MARIYAM RAWAT
Mariyam is a Senior Director within Healthcare Strategic Communications for FTI Consulting. She has also worked with
organisations incluidng multinationals, top FTSE, SMEs and not-for-profit,
such as The Boots Company, Pfizer, Reckitt Benckiser and the NHS. Mariyam holds a BSc Honours degree and a MBA
specialising in post-merger integration. With more than 15 years’ experience working in healthcare and life sciences communications, Mariyam was recently seconded to the World Economic Forum to manage the transition of a wellness project. The initiative involved the engagement and management of more than 150 stakeholders, transcending several geographies and sectors.
|
FTI Consulting
patients greater knowledge of their own health, and assess what the best treatment is for them. With access to quality information about the cost and available treatments, patients are able to influence healthcare systems, prompting companies and payers to review their policies and approach to market access. If industry, academia and the health service
are to truly collaborate for the benefit of patient population, a mechanism to interface at a national and local level is required. This will help local NHS services find the research and informatics, services, education and training they need to be innovative. As a result 15 have been created across the
UK to develop a systematic approach and ensure innovation. They will also facilitate participation by global partners, including academia, industry and healthcare practitioners.
Conclusion It is clear that the global healthcare and life sciences landscape will continue to evolve over time. In the UK pressures on the NHS, combined with the loss of its life sciences R&D leadership and subsequent effect on GDP, resulted in the government launching an integrated and ambitious strategy. It aims to accelerate the UK’s leadership in 21st century medicine by addressing healthcare needs, while driving innovation, and acknowledging that you cannot build a sustainable life sciences industry on research alone. A fresh, evolutionary approach is needed if the UK is to provide affordable solutions to the NHS and effectively compete in the global market of the future. The healthcare and life sciences sectors also need
to evolve. A more holistic approach will support clients as the traditional boundaries continue to shift. Affordable, effective, timely and equitable healthcare is not unique to any one institution, organisation or country. While landscapes, philosophy and infrastructure may differ between the UK’s NHS and GCC nations, there are significant similarities in the challenges faced by healthcare systems. The experts at FTI provide solutions for clients
so that they can optimise their performance in the short term and prepare for the inevitable challenges of the future. The FTI Consulting professionals take a strategic approach to engaging stakeholders, including internal audiences, investors, partners, patients, payers, policymakers, providers, and those at the board level. Whether the challenge is to develop a new health economic model, manage the pressures associated with R&D productivity, succeed in the face of global pricing pressures or deliver meaningful, sustained and embedded transformation in healthcare systems at a local and national level, FTI’s healthcare and life sciences professionals have the knowledge and expertise to guide you.
Further information Tel: +44 (0) 20 3727 1000
www.fticonsulting.co.uk
global-opportunity.co.uk Issue 01 | Global Opportunity Healthcare 2015 77
IMAGE:
WWW.SHUTTERSTOCK.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128